Compiled by Rupeestop LLP, SEBI RIA INA000022701. NAV as on 30 Sept 2026. Factsheet Jun 2026. About · Disclosures
HDFC Pharma and Healthcare Fund Direct Plan Growth
HDFC Mutual FundSectoral Pharma and HealthcareDirectGrowthVery high risk
NAV
₹21.944
As on 30 Sept 2026
Vs category
| Period | This fund | Category | Rank |
|---|---|---|---|
| 1 year | +27.80% | — | — |
| 3 year | +30.22% | — | — |
| 5 year | +30.22% | — | — |
Returns
From NAVs through 30 Sept 2026
1Y
+27.80%
Total
3Y
+30.22%
p.a.
5Y
+30.22%
p.a.
SI
+30.22%
p.a.
Calendar years
+13.96%2023
+52.22%2024
+2.42%2025
+23.95%2026 YTD
Rolling 1-year · 24 overlapping windows
+5.63%avg +25.32%+66.05%
Fund facts
Fund details from the Jun 2026 factsheet
Fund size
₹3,310.64 Cr
Expense ratio
0.92%
Exit load
None
Lock-in
None
BenchmarkBSE Healthcare TRI
Launched03 Oct 2023
Risk levelVery high
StructureOpen Ended
ISININF179KC1HO1
Where the money is invested
Split by asset type.
By asset type
Equity98.70%
Cash1.30%
What the fund holds
35 holdings · portfolio as on 30 May 2026
- 9.2%Sun Pharmaceuticals Industries LtdHealthcare
- 8.02%Divi's Laboratories LtdHealthcare
- 5.45%Lupin LtdHealthcare
- 5.26%Max Healthcare Institute Ltd Ordinary SharesHealthcare
- 5.18%Aster DM Healthcare Ltd Ordinary SharesHealthcare
- 4.92%Cipla LtdHealthcare
- 4.5%Acutaas Chemicals LtdBasic Materials
- 4.36%Alkem Laboratories LtdHealthcare
- 4.15%Anthem Biosciences LtdHealthcare
- 3.5%Ipca Laboratories LtdHealthcare
Concentration
Top 5 weight
33.12%
Top 10 weight
54.55%
Avg turnover
43.33%
Risk and quality measures
How steady the returns have been.
Return quality
Sharpe
1
Better than category avg 0.48
Alpha
9.59
Return above the benchmark
Information ratio
2.12
Consistency of outperformance
Risk
Std deviation
16.31%
How much returns swing
Beta
1.04
Below category avg 0.94
R-squared
97.1%
How closely it tracks the benchmark
Who manages this fund
2 fund managers
- NMNikhil Mathur2.5 years in the industryRuns 1 scheme
- DMDhruv Muchhal2.7 years in the industryRuns 46 schemes
Other Sectoral Pharma and Healthcare funds
ITI Pharma and Healthcare Fund - Direct Plan - GrowthdirectCompare
Tata India Pharma and Healthcare Fund Direct Plan GrowthdirectCompare
Whiteoak Capital Pharma and Healthcare Fund - Direct Plan - GrowthdirectCompare
Aditya Birla Sunlife Life Pharma and Healthcare Fund Direct GrowthdirectCompare
ICICI Prudential Pharma Healthcare and Diagnostics (p.h.d) Fund Direct Plan Growth-InsureddirectCompare- ITI Pharma and Healthcare Fund - Direct Plan - IDCW PayoutdirectCompare
- ITI Pharma and Healthcare Fund - Direct Plan - IDCW ReinvestmentdirectCompare
- HDFC Pharma and Healthcare Fund Direct Plan IDCW ReinvestmentdirectCompare
SIP illustration
Rate
+30.22%
Invested
₹6,00,000
Illustrated
₹38,21,704
₹5,000/mo × 10 years at this fund's 3Y CAGR. Illustration, not a forecast. SIP calculator
Other versions
- regularGrowthHDFC Pharma and Healthcare Fund Regular Plan GrowthNAV ₹17.38
- regularIDCWHDFC Pharma and Healthcare Fund Regular Plan IDCW ReinvestmentNAV ₹17.38
- directIDCWHDFC Pharma and Healthcare Fund Direct Plan IDCW ReinvestmentNAV ₹17.82
- directIDCWHDFC Pharma and Healthcare Fund Direct Plan IDCW ReinvestmentNAV ₹17.82
- regularIDCWHDFC Pharma and Healthcare Fund Regular Plan IDCW ReinvestmentNAV ₹17.38
FAQ
What is HDFC Pharma and Healthcare Fund Direct Plan Growth NAV today?
- The latest NAV of HDFC Pharma and Healthcare Fund Direct Plan Growth is ₹21.944 as on 30 Sept 2026.
How has HDFC Pharma and Healthcare Fund Direct Plan Growth performed vs its category?
- 1-year return +27.80%. Past performance does not guarantee future returns.
What are the returns of HDFC Pharma and Healthcare Fund Direct Plan Growth?
- Trailing returns from published NAVs: 1 year +27.80%, 3 year +30.22% a year, 5 year +30.22% a year, since our first NAV +30.22% a year. Past performance does not guarantee future returns.
How would a SIP in HDFC Pharma and Healthcare Fund Direct Plan Growth have been illustrated?
- The SIP illustration on this page uses ₹5,000 a month for 10 years at this fund's 3-year annualised return of +30.22%. It is not a forecast.
What is the expense ratio and fund size of HDFC Pharma and Healthcare Fund Direct Plan Growth?
- For HDFC Pharma and Healthcare Fund Direct Plan Growth, the expense ratio is 0.92% and fund size (AUM) is ₹3,310.64 Cr.
What is the ISIN of HDFC Pharma and Healthcare Fund Direct Plan Growth?
- The ISIN for HDFC Pharma and Healthcare Fund Direct Plan Growth is INF179KC1HO1.
Mutual fund investments are subject to market risks. Read all scheme related documents carefully before investing. Past performance does not guarantee future returns and is not an indicator of future results.
Figures on this page come from published NAVs and the scheme's monthly factsheet. They are for information only and are not investment advice or a recommendation to buy or sell any scheme.